Altium Capital Management LP Larimar Therapeutics, Inc. Call Options Transaction History
Altium Capital Management LP
- $29.1 Million
- Q1 2025
Call Options
2 transactions
Others Institutions Holding LRMR
# of Institutions
108Shares Held
64.5MCall Options Held
93.5KPut Options Held
68K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$42 Million1.16% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$12 Million0.27% of portfolio
-
Janus Henderson Group PLC London, X05.57MShares$11 Million0.01% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.78MShares$9.46 Million5.31% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$6.76 Million6.65% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $85.7M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...